Enterobacteriaceae Infections is an indication for drug development with over 200 pipeline drugs currently active. According to GlobalData, preregistered drugs for Enterobacteriaceae Infections have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Enterobacteriaceae Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Enterobacteriaceae Infections overview
Enterobacteriaceae are a large family of Gram-negative bacteria that include many commensal and pathogenic species. They can cause various infections in humans and animals, such as urinary tract infections, bloodstream infections, pneumonia, and intra-abdominal infections. Enterobacteriaceae are facultative anaerobes that ferment sugars and reduce nitrate to nitrite. They are usually rod-shaped and motile, but some genera are nonmotile. They lack cytochrome c oxidase and produce endotoxins that can trigger a systemic inflammatory response.
For a complete picture of PTSR and LoA scores for drugs in Enterobacteriaceae Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
